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Abstract
Health-related quality of life was a secondary endpoint in the phase III GALLIUM study in previously untreated patients with
follicular lymphoma who were treated with rituximab- or obinutuzumab-chemotherapy. Patients were randomized 1:1 to receive
induction therapy with obinutuzumab- or rituximab-chemotherapy and maintenance in responders. Health-related quality of life
was assessed using the Functional Assessment of Cancer Treatment-Lymphoma questionnaire, incorporating well-being and
lymphoma-specific subscales. Assessments were performed at baseline, and during induction, maintenance, and follow-up
(maximum 84 months). Clinically meaningful responses were defined by minimally important difference values. Of 1202
randomized patients (median follow-up 57.4 months), 557/601 (92.7%; obinutuzumab-chemotherapy) and 548/601 (91.2%;
rituximab-chemotherapy) completed all Functional Assessment of Cancer Treatment-Lymphoma scales at baseline. Mean base-
line health-related quality of life scores were similar between both arms, with all patients having some functional impairment and
lymphoma symptoms. Over the course of treatment, mean health-related quality of life remained similar in both arms. Equal
proportions of patients in both arms achievedminimally important difference by the Functional Assessment of Cancer Treatment-
Lymphoma lymphoma-specific subscale and summary scales throughout induction, maintenance, and follow-up. On each
summary scale, ~ 50% of patients in each arm achieved minimally important difference by maintenance month 2. In
GALLIUM, similar improvements in health-related quality of life were seen with obinutuzumab- and rituximab-chemotherapy,
suggesting that both treatments reduced lymphoma-related symptoms, and treatment-related side effects did not abrogate these
improvements in well-being. ClinicalTrials.gov identifier: NCT01332968.
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Introduction
Follicular lymphoma (FL) encompasses approximately 70%
of indolent non-Hodgkin lymphomas (iNHL) and 22% of all
NHLs [1]. Rituximab (R), a type I monoclonal antibody
(mAb), plus chemotherapy (R-chemo) induction, and mainte-
nance therapy has resulted in improved outcomes for patients
with FL [2–5]. Nevertheless, 20–35% of patients experience
progressive disease, relapse, or death within 2 years [4, 6],
with early disease progression associated with worse progno-
sis [7, 8].
Obinutuzumab (GA101; G) is the first glycoengineered,
type II, humanized anti-CD20 mAb, promoting enhanced
antibody-dependent cellular toxicity and direct cell death
against B cell malignancies when compared with type I
mAbs [9]. The phase III GALLIUM study (NCT01332968)
evaluated G-chemotherapy (G-chemo) versus R-chemo as in-
duction therapy in patients with previously untreated,
advanced-stage FL, followed by maintenance with the same
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antibody in responders. In the primary analysis of this study
(data cut-off January 31, 2016), the primary endpoint of
investigator-assessed progression-free survival (PFS) was
met, with an improvement in PFS shown for patients treated
with G-chemo versus those treated with R-chemo (median
follow-up, 34.5 months; hazard ratio 0.66; 95% confidence
interval 0.51–0.85; p = 0.001) [10]. Adverse events (AEs)
were consistent with the known safety profiles of both study
treatments [10].
Despite the improvements in patient outcomes that have
come with advancements in immunochemotherapy, the treat-
ment of conditions like FL can often have a more negative
impact on the patient than the disease itself [11]. Meaningful
improvements in health-related quality of life (HRQoL) and
the effect that serious or persistent treatment-related symp-
toms have on patients are important factors to consider, nota-
bly with the increased chances of prolonged survival follow-
ing treatment.
Several studies have investigated the impact of treatment
on HRQoL in patients with iNHL. In a population of patients
with FL, those who were newly diagnosed with active disease
had similar HRQoL compared with patients that were either in
partial/complete remission or disease free, while having better
HRQoL than those who had relapsed [11]. In the phase III
GADOLIN trial of patients with relapsed/refractory iNHL,
patients treated with G-bendamustine (B) versus B had a de-
layed time to worsening and more reports of clinically mean-
ingful improvements in HRQoL [12].
However, previous analyses have primarily been cross-
sectional studies, with none having compared G-chemo
with R-chemo in a population of patients with FL. In this
secondary analysis of the GALLIUM study, we compared
the changes in HRQoL in first-line patients with FL treat-
ed with G-chemo or R-chemo, investigating the potential
differences in patient-reported outcomes (PROs) between
the two treatments.
Methods
Study design
GALLIUM was a phase III, open-label, parallel-group study.
Patients with previously untreated grade 1–3a FL were ran-
domized 1:1 to receive induction therapy with G plus chemo-
therapy (cyclophosphamide, doxorubicin, vincristine, and
prednisone [CHOP]; cyclophosphamide, vincristine, and
prednisone [CVP]; or B). Six to eight cycles of chemotherapy
were prescribed, depending on the selected chemotherapy
(chosen upfront by investigators at each site; all patients at
the same site received the same regimen). Patients achieving
at least a partial response on contrast-enhanced computed
tomography received maintenance with the same antibody
for 2 years or until progressive disease.
Patient selection, study methods, and treatment are de-
scribed in detail within the Online Resource (Methods) and
elsewhere [10].
Patient-reported HRQoL assessments
HRQoL was assessed using the Functional Assessment of
Cancer Treatment-Lymphoma (FACT-Lym) questionnaire
[13], incorporating the FACT-General (FACT-G) scale (phys-
ical well-being [PWB], functional well-being [FWB], emo-
tional well-being [EWB], and social/family well-being
[SWB]) and the FACT-Lym lymphoma-specific (LYMS) sub-
scale. Summary scales FACT-Lym trial outcome index (TOI),
FACT-G, and Total (TOT) were also calculated. Further de-
tails of these questionnaires can be found within the Online
Resource (Methods).
Assessments were performed at baseline (cycle
[C]1 day [D]1), C3D1, end of induction, during main-
tenance months 2 and 12, at the end of maintenance
(month 24), and then every 12 months during follow-
up, up to 84 months.
Clinically meaningful responses were defined by min-
imally important difference (MID) values in FACT-Lym
and FACT-G. A MID reflects the smallest difference in a
score that is considered to be clinically important to the
patient [14–16]. Patients who achieved an improved
score versus baseline, reaching the upper limits of
FACT-Lym (LYMS, ≥ 3 points; TOI, ≥ 6 points; TOT,
≥ 7 points) and FACT-G (≥ 2–3, excluding the SWB
scale), were classified as responders, with differences be-
tween treatment groups assessed [15, 16]. Higher FACT-
Lym scores indicate improved functioning, HRQoL, and
health status.
Statistical analysis
PRO analyses included all randomized patients who had
a baseline measure and ≥ 1 post-baseline assessment.
Missing values were not imputed; however, prorated
scores were calculated based on developed guidelines
[17]. Analyses were performed separately for patients
with FL versus the overall population (data cut-off
February 12, 2018).
Questionnaire completion rates were calculated. For
each FACT-Lym questionnaire scale, descriptive statis-
tics at each visit and changes from baseline are present-
ed. After baseline FACT-Lym LYMS, TOI, TOT, and
FACT-G were evaluated, mean score changes from base-
line were calculated for each time point. Finally, the
proportion of patients with FL achieving the MID for
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each scale, i.e., a clinically meaningful response, was
assessed.
Here we present only the results up to month 48, due
to the dense censoring that occurs after this time point;
results up to month 84 can be found within the Online
Resource.
Results
Disposition and updated analysis
In total, 1202 patients with FL were randomized to receive
either G-chemo (n = 601) or R-chemo (n = 601) in the
GALLIUM trial (Online Resource: Supplementary Fig. 1).
Baseline demographic and disease characteristics were well-
balanced between arms [10].
The efficacy and safety findings of the updated GALLIUM
analysis (data cut-off February 12, 2018; median follow-up,
57.4 months) were consistent with the primary analysis; G-
chemo continued to provide clinically meaningful improve-
ments in PFS relative to R-chemo (4-year PFS rate, 78.1% vs.
67.2%; hazard ratio 0.73; 95% confidence interval 0.59–0.90;
p = 0.0034) [18]. No new safety signals were identified, with
grade 3–5 AEs and serious AEs being more common in pa-
tients treated with G-chemo versus R-chemo, in line with the
primary analysis [10, 18].
Questionnaire completion rates
In the G-chemo and R-chemo arms, 557/601 (92.7%) and
548/601 (91.2%) patients completed all scales of FACT-Lym
assessments at baseline, respectively. Throughout the study,
the percentage of patients who completed all scales of FACT-
Lym was well-balanced between arms. Although completion
rates did decline over the course of treatment, low rates of
attrition during induction, maintenance, and follow-up (up to
month 48) were seen (Fig. 1). The proportion of patients com-
pleting FACT-Lym assessments decreased beyond this time
point, and patient numbers declined substantially up to
follow-up month 84 (Online Resource: Supplementary
Table 1).
Absolute and mean change in HRQoL questionnaire
scores from baseline
Mean baseline values for FACT-Lym composite scores TOI
and TOT and FACT-Lym LYMS subscale and individual
FACT-G subscales (PWB, FWB, EWB, and SWB) were com-
parable across treatment arms (Online Resource:
Supplementary Fig. 2). In both treatment arms, patients exhib-
ited some level of baseline impairment according to function-
ing and lymphoma symptom subscales, noted by mean scores
between 5 and 15 points below the possible maximum (de-
pending on the subscale).
For FACT-G assessments, an initial negative mean change
from baseline (C1D1) by PWB and FWB subscales was re-
ported (C3D1, G-chemo vs. R-chemo, PWB – 0.21 vs. – 0.91;
FWB – 0.06 vs. – 0.30; Fig. 2a and b, respectively).
Conversely, EWB increased rapidly by the first time point in
both treatment arms (C3D1, G-chemo vs. R-chemo, 1.36 vs.
1.49; Fig. 2c). Modest increases were then reported in both
treatment arms for the PWB, FWB, and EWB scales up to
follow-up month 48. SWB scores decreased versus baseline
for both G-chemo and R-chemo (follow-up month 48, − 1.15
vs. – 0.78; Fig. 2d). Despite the increases seen for PWB,
FWB, and EWB, scores only exceeded the threshold for clin-
ically meaningful change on the FWB subscale (> 2) for pa-
tients treated with R-chemo. Beyond follow-up month 48,
PWB scores continued to increase, with MID (> 2–3)
achieved between months 72 and 84 (Online Resource:
Supplementary Table 2).
Over the course of treatment, similar trends were observed
in patients treated with G-chemo and R-chemo up to follow-
up month 48. A rapid increase in FACT-Lym LYMS was seen
from baseline to the first time point for both G-chemo and R-
chemo (C3D1, 2.73 vs. 2.04, respectively). The mean change
from baseline continued to increase at each time point for
FACT-Lym LYMS (Fig. 3a), TOI (Fig. 3b), and TOT
(Fig. 3c), up to maintenance month 2, at which point MID
was achieved (G-chemo vs. R-chemo, LYMS [≥ 3] 4.52 vs.
4.80; TOI [≥ 6] 7.17 vs. 6.22; and TOT [≥ 7] 8.13 vs. 8.40,
respectively). From maintenance month 2 up to follow-up
month 48, the mean change from baseline scores levelled off
for all scales (for G-chemo vs. R-chemo, LYMS 4.76 vs. 4.50;
TOI 8.51 vs. 7.23; TOT 9.48 vs. 8.98, respectively). Mean
changes from baseline continued to increase up to follow-up
month 84 in all scales in both arms, excluding the FACT-Lym
LYMS assessment in patients treated with R-chemo (Online
Resource: Supplementary Table 3).
Clinically meaningful improvement in FACT-Lym
LYMS subscale and FACT-Lym composite (TOI
and TOT) scores
Equal proportions of patients in the G-chemo and R-chemo
arms achieved MID by the FACT-Lym LYMS score, and the
composite scores TOI and TOT, throughout induction, main-
tenance, and follow-up (Fig. 4a, b, and c, respectively). At the
first assessment (C3D1), ≥ 30% of patients evaluated achieved
MID, with approximately 50% of patients reporting clinically
meaningful improvements at maintenance month 2 and con-
tinuing to respond at follow-up month 48 (G-chemo vs. R-
chemo, LYMS, 54.2% vs. 55.5%; TOI, 51.8% vs. 49.7%;
TOT, 49.7% vs. 48.0%, respectively). Results beyond
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follow-up month 48 are reported in Online Resource:
Supplementary Table 4.
Discussion
For first-line patients with FL, treatment with G-chemo results
in improved PFS when compared with the current standard-
of-care treatment, R-chemo [10, 18]. However, achieving im-
provements in PROs is just as important as improving clinical
outcomes such as PFS. In the current analysis of the
GALLIUM study, similar improvements in HRQoLwere seen
with G-chemo and R-chemo treatment in patients with FL,
with no clear differences between treatment groups reported
at any time point. Within the context of improved PFS, these
results further support the positive benefit-risk balance of G-
chemo over R-chemo in previously untreated patients with
FL.
In the current study, PWB, FWB, EWB, and SWB scores
were similar at baseline, albeit lower than previously reported
values in patients with newly diagnosed active FL. In a study
by Pettengell et al. of patients with newly diagnosed active
disease, scores were higher in all FACT-Lym subscales (range
0–8 points) versus those enrolled in GALLIUM [11]. It is
important to note that some of the active disease-newly diag-
nosed group were on a watch and wait strategy, which could
indicate a lower disease burden compared with the patients
enrolled in GALLIUM [11]. A study of HRQoL in long-
term survivors of iNHL and aggressive NHL found that, at
diagnosis, patients with stage III/IV aggressive NHL had sig-
nificantly worse HRQoL than those with stage I/II aggressive
or iNHL [19]. These findings demonstrate that first-line pa-
tients with FL may experience an improved HRQoL com-
pared with patients with relapsed disease (although worsened
compared with the general population [20]) and support the
view that HRQoL differs according to disease state.
Over the course of treatment, similar improvements in
FACT-Lym composite scores, and thus HRQoL, were ob-
served in both treatment arms. At no time point up to
follow-up, month 48 was the average HRQoL of patients re-
ceiving G-chemo clinically worse than those receiving R-che-
mo. Patients in both arms experienced clinically meaningful
improvements in FACT-Lym LYMS and in the summary
scales (i.e., TOI and TOT). These results suggest that
lymphoma-related symptoms improved in both treatment
arms to a degree recognizable by patients, subsequently driv-
ing improvement in composite summary scales. Importantly,
this was despite the higher AE rates observed in the G-chemo
arm as reported in both the primary and updated analyses of
GALLIUM [10, 18].
Findings are further supported by the number of patients
reporting clinically meaningful improvements in both treat-
ment arms, with approximately half having achieved a MID
by maintenance month 2, sustained up to follow-up month 48.
When coupled with lack of deterioration in PWB and FWB,
these results suggest that improvements in well-being were
not abrogated by the increased number of treatment-related
side effects reported in patients receiving G-chemo versus
R-chemo. This is in line with results reported from the
GADOLIN study of patients with relapsed/refractory iNHL,
whereby patients treated with G-B had improved HRQoL
scores when compared with those treated with B alone, and
benefits in PFS seen with G-B were not abrogated by
treatment-related toxicity [12]. Previously, the majority of pa-
tients who survived iNHL still feared the probability of relapse
and second malignancy [19]. Therefore, patients who have
responded to therapy should still be monitored post-response
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Fig. 1 FACT-Lym questionnaire
completion data for R-chemo vs.
G-chemo. The table below the
graph shows the number of
patients still receiving treatment
who completed all FACT-Lym
scales at the specified time point.
C, cycle; chemo, chemotherapy;
D, day; EOI, end of induction;
EOM, end of maintenance; FACT-
Lym, Functional Assessment of
Cancer Treatment-Lymphoma;
FU, follow-up; G, obinutuzumab;
Maint, maintenance; R, rituximab
Fig. 2 Mean change from baseline in FACT-G PWB, FWB, EWB, and
SWB, by treatment arm. a PWB, b FWB, c EWB, and d SWB. *Changes
of 2–3 points are considered meaningful on the PWB, FWB, and EWB
scales. A meaningful change has not yet been defined for the SWB scale.
The number of patients still receiving treatment who completed the
FACT-G questionnaire at the specified time point is specified below the
graph. C, cycle; chemo, chemotherapy; D, day; EOI, end of induction;
EOM, end of maintenance; EWB, emotional well-being; FACT-G,
Functional Assessment of Cancer Treatment-General; FU, follow-up;
FWB, functional well-being; G, obinutuzumab; Maint, maintenance;
MID, minimally important difference; PWB, physical well-being; R,
rituximab; SWB, social/family well-being
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to ensure improvements in HRQoL are sustained. In the cur-
rent analysis, slight improvements in average scores, though
less than the MID, were seen with PWB, FWB, and EWB
scores, with very small deterioration (approximately − 1
point) seen in the SWB scores, throughout the study period
in both treatment arms. When interpreting these data, it is
important to consider that GALLIUM was an open-label
study, and patients were aware of their treatment regimen. It
is possible that the initial post-treatment HRQoL scores may
reflect a certain degree of expectation toward treatment out-
come, which may have impacted patients’ reporting of
HRQoL in either treatment arm. Any influence that knowl-
edge of therapy may have had on patient reporting of HRQoL
was likely to have resolved over the course of treatment as
patients either experienced or did not experience improve-
ments in their condition.
At the first time point in the GALLIUM and GADOLIN
trials (C3D1 and C5D1, respectively), a decline compared
Fig. 3 Mean change from
baseline in FACT-Lym LYMS,
TOI, and TOT scores, by
treatment arm. a LYMS, b TOI,
and c TOT. The number of
patients still receiving treatment
who completed the FACT-Lym
questionnaire at the specified time
point is specified below the graph.
C, cycle; chemo, chemotherapy;
D, day; EOI, end of induction;
EOM, end of maintenance; FACT-
Lym, Functional Assessment of
Cancer Treatment-Lymphoma;
FU, follow-up; G, obinutuzumab;
LYMS, lymphoma-specific;
Maint, maintenance; MID,
minimally important difference;
R, rituximab; TOI, trial outcome
index; TOT, total
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with baseline in both PWB and FWBwas reported, with mod-
est increases reported thereafter [10, 12]. As patients enrolled
in GALLIUM were previously untreated, this decline indi-
cates further measures should be taken during early induction
to ensure the provision of G plus combination therapy does
not negatively influence physical and functional well-being.
In GALLIUM, the chemotherapy regimen was selected
upfront by each participating center, with all patients at the
same center receiving the same regimen (i.e., B, CHOP, or
CVP). The results reported here do not address differences
in HRQoL that may have been seen between chemotherapy
regimens. Furthermore, patients received either six or eight
cycles of chemotherapy depending on chemotherapy regimen,
which may also have led to subgroup differences in HRQoL
that have not been addressed here. Additionally, there is the
possibility that the length of time between assessments may
have missed changes that occurred in symptom burden during
the initial weeks of treatment; a finding that has been noted
Fig. 4 Proportion of patients with
FL achievingMID on FACT-Lym
LYMS score (≥ 3), TOI score (≥
6), and TOT score (≥ 7). a LYMS
(≥ 3), b TOI (≥ 6), and c TOT (≥
7) score. The number of patients
still receiving treatment who
achieved MID at the specified
time point is specified below the
graph. C, cycle; chemo,
chemotherapy; D, day; EOI, end
of induction; EOM, end of
maintenance; FACT-Lym,
Functional Assessment of Cancer
Treatment-Lymphoma; FL,
follicular lymphoma; FU, follow-
up; G, obinutuzumab; LYMS,
lymphoma-specific; Maint,
maintenance; MID, minimally
important difference; R,
rituximab; TOI, trial outcome
index; TOT, total
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outside of hematology studies (i.e., non-small-cell lung cancer
during the first week following chemotherapy treatment) [21].
Therefore, the timing of HRQoL assessment should be care-
fully considered in the design of future trials, as this may
influence the chances of detecting differences between treat-
ment regimens.
It should be noted that questionnaire completion rates were
high at baseline, and a low rate of attrition was observed
throughout the study in both treatment arms. This suggests
that issues with non-compliance should not deter the imple-
mentation of PRO measures in the design of future clinical
trials. In addition, the high compliance rates provide confi-
dence in the representativeness of the HRQoL in patients treat-
ed with G-chemo and R-chemo in the GALLIUM trial.
This analysis of the secondary endpoint HRQoL of the
GALLIUM study sought to compare changes in HRQoL in
first-line patients with FL treated with G- or R-based chemo-
therapy. These results demonstrate that aspects of HRQoL and
lymphoma symptoms improved over the course of treatment,
and there were a high number of patients in both treatment
arms that experienced a clinically meaningful improvement in
HRQoL. In addition, as PRO scores were similar between
arms throughout induction, maintenance, and follow-up,
treatment-related toxicity did not abrogate improvements in
well-being in those patients who did not experience clinically
meaningful responses. Furthermore, there was no evidence of
cumulative side effects. Both clinical outcomes and PROs
should be considered in future clinical trials in patients with
FL.
Acknowledgments The authors would like to thank all of the patients
who participated in the GALLIUM study, and acknowledge all of the
study investigators and their staff as well as the GALLIUM study team.
Authors’ contributions Conception and design, AD and PT; Provision of
study materials or patients, AD, HQ, TK, JMS, MH, RP, and SS;
Collection and assembly of data, AD; Data analysis and interpretation,
AD, PT, HQ, TK, and RP; Manuscript writing, all authors; Final approval
of manuscript, all authors; Accountable for all aspects of the work, all
authors.
Funding information GALLIUM was sponsored by the F. Hoffmann-La
Roche Ltd. Third-party medical writing assistance, under the direction of
AndrewDavies, was provided by the Russell Craddock and Louise Profit
of Gardiner-Caldwell Communications, and was funded by the F.
Hoffmann-La Roche Ltd.
Data availability Qualified researchers may request access to individual
patient level data through the clinical study data request platform (www.
clinicalstudydatarequest.com). Further details on Roche’s criteria for
eligible studies are available here (https://clinicalstudydatarequest.com/
Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on
Roche’s Global Policy on the sharing of clinical information and how
to request access to related clinical study documents, see here (https://
www.roche.com/research_and_development/who_we_are_how_we_
work/clinical_trials/our_commitment_to_data_sharing.htm).
Compliance with ethical standards
Conflict of interest AD, research funding (Celgene), research support
(F. Hoffmann-La Roche Ltd., Gilead/Kite, Takeda, GSK, Karyopharm,
Pfizer, Acerta Pharma), advisory board participation (Celgene, F.
Hoffmann-La Roche Ltd., Gilead/Kite,Takeda, Karyopharm, Acerta
Pharma), honoraria (Celgene, F. Hoffmann-La Roche Ltd., Gilead/Kite,
Takeda, Janssen, Pfizer, Acerta Pharma), and travel to scientific confer-
ences (Takeda). PT, employment (Genentech Inc). HQ, research funding
(Celgene, Amgen) and advisory board participation (Celgene, Amgen,
GSK, Karyopharm, Takeda). SR, advisory board participation, speaker
fees, and honoraria (F. Hoffmann-La Roche Ltd., Takeda, Novartis,
Gilead, Sandoz). TK, research funding (Chugai, Takeda, Solaisia, Ono,
Gilead, MSD, Zenyaku) and personal fees (Chugai, Ono, Gilead, MSD,
Zenyaku, Bristol, Kyowa Kirin, Eisai, Janssen). RP, personal fees (CTI
Life Sciences Ltd., Roche, Servier, Takeda) and advisory board partici-
pation (CTI Life Sciences Ltd., G1 Therapeutics Inc., Immune Design,
Pfizer, F. Hoffmann-La Roche Ltd., Servier, Takeda, TEVA). JMS, hon-
oraria (F. Hoffmann-La Roche Ltd., Gilead, Janssen, Celgene, Novartis,
Mundipharma, Kern-Pharma, Sanofi) and advisory board participation (F.
Hoffmann-La Roche Ltd., Gilead, Janssen, Celgene, Celltrion, Sandoz,
Bristol-Myers Sqibb). MH, honoraria (Novartis, Amgen, F. Hoffmann-La
Roche Ltd) and advisory board participation (Celgene, Takeda). SS, ad-
visory board participation (Takeda, NAPP Pharmaceuticals) and personal
fees (Janssen, Novartis). AK and WL, employment (F. Hoffmann-La
Roche Ltd). The remaining authors declare no conflicts of interest.
Ethical approval GALLIUM was conducted in accordance with the
Declaration of Helsinki and the International Council for Harmonisation
guidelines for Good Clinical Practice. The protocol was approved by the
ethics committees of participating centers and is registered at
ClinicalTrials.gov.
Informed consent Informed consent was obtained from all individual
participants included in the study.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons licence, and indicate if
changes weremade. The images or other third party material in this article
are included in the article's Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in the
article's Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view a
copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. (1997) A clinical evaluation of the International Lymphoma Study
Group classification of non-Hodgkin's lymphoma. The Non-
Hodgkin's Lymphoma Classification Project. Blood 89(11):3909–
3918
2. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E,
Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S,
Fischer T, Kropff M, Reis HE, Freund M, Wormann B, Fuchs R,
Planker M, Schimke J, Eimermacher H, Trumper L, Aldaoud A,
Parwaresch R, UnterhaltM (2005) Frontline therapy with rituximab
added to the combination of cyclophosphamide, doxorubicin, vin-
cristine, and prednisone (CHOP) significantly improves the
Ann Hematol
outcome for patients with advanced-stage follicular lymphoma
compared with therapy with CHOP alone: results of a prospective
randomized study of the German Low-Grade Lymphoma Study
Group. Blood 106(12):3725–3732. https://doi.org/10.1182/blood-
2005-01-0016
3. Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A,
Raposo JC, Offner FC, Gomez-Codina J, Belch A, Cunningham D,
Wassner-Fritsch E, Stein G (2008) Phase III study of R-CVP com-
pared with cyclophosphamide, vincristine, and prednisone alone in
patients with previously untreated advanced follicular lymphoma. J
Clin Oncol : 26(28):4579–4586. https://doi.org/10.1200/jco.2007.
13.5376
4. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von
Grunhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M,
Balser C, Kaiser U, Weidmann E, Durk H, Ballo H, Stauch M,
Roller F, Barth J, Hoelzer D, Hinke A, Brugger W (2013)
Bendamustine plus rituximab versus CHOP plus rituximab as
first-line treatment for patients with indolent and mantle-cell lym-
phomas: an open-label, multicentre, randomised, phase 3 non-
inferiority trial. Lancet (London, England) 381(9873):1203–1210.
https://doi.org/10.1016/s0140-6736(12)61763-2
5. Salles GA, Seymour JF, Feugier P, Offner F, Lopez-Guillermo A,
Belada D, Xerri L, Bouabdallah R, Catalano J, Pauline B, Caballero
D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S,
Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T,
Ferme C, Gomes da Silva M, Sebban C, Lister A, Estell JA,
Milone G, Sonet A, Coiffier B, Tilly H (2013) Updated 6 year
follow-up of the PRIMA study confirms the benefit of 2-year ritux-
imab maintenance in follicular lymphoma patients responding to
frontline immunochemotherapy. Blood 122(21):509
6. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J,
Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P
(2005) CVP chemotherapy plus rituximab compared with CVP as
first-line treatment for advanced follicular lymphoma. Blood
105(4):1417–1423. https://doi.org/10.1182/blood-2004-08-3175
7. Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers
CR, Hainsworth JD, Maurer MJ, Cerhan JR, Link BK, Zelenetz
AD, Friedberg JW (2015) Early relapse of follicular lymphoma
after rituximab plus cyclophosphamide, doxorubicin, vincristine,
and prednisone defines patients at high risk for death: an analysis
from the National LymphoCare Study. J Clin Oncol : 33(23):2516–
2522. https://doi.org/10.1200/jco.2014.59.7534
8. Seymour JF, Marcus R, Davies A, Gallop-Evans E, Grigg A,
Haynes A, Herold M, Illmer T, Nilsson-Ehle H, Sokler M,
Dunzinger U, Nielsen T, Launonen A, Hiddemann W (2018)
Association of early disease progression and very poor survival in
the GALLIUM study in follicular lymphoma: benefit of
obinutuzumab in reducing the rate of early progression.
Haematologica. https://doi.org/10.3324/haematol.2018.209015
9. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S,
Grau R, Gerdes C, Nopora A, van Puijenbroek E, Ferrara C,
Sondermann P, Jager C, Strein P, Fertig G, Friess T, Schull C,
Bauer S, Dal Porto J, Del Nagro C, Dabbagh K, Dyer MJ,
Poppema S, Klein C, Umana P (2010) Increasing the efficacy of
CD20 antibody therapy through the engineering of a new type II
anti-CD20 antibody with enhanced direct and immune effector cell-
mediated B-cell cytotoxicity. Blood 115(22):4393–4402. https://
doi.org/10.1182/blood-2009-06-225979
10. Marcus R, Davies A, AndoK,KlapperW, Opat S, Owen C, Phillips
E, Sangha R, Schlag R, Seymour JF, Townsend W, Trněný M,
Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M,
Hiddemann W (2017) Obinutuzumab for the first-line treatment of
follicular lymphoma. New Engl J Med 377(14):1331–1344. https://
doi.org/10.1056/NEJMoa1614598
11. Pettengell R, Donatti C, Hoskin P, Poynton C, Kettle PJ, Hancock
B, Johnson S, Dyer MJ, Rule S, Walker M, Wild D (2008) The
impact of follicular lymphoma on health-related quality of life. Ann
Oncol : 19(3):570–576. https://doi.org/10.1093/annonc/mdm543
12. Cheson BD, Trask PC, Gribben JG, Dimier N, Kimby E,
Lugtenburg PJ, Thieblemont C, Wassner-Fritsch E, Launonen A,
Sehn LH (2017) Health-related quality of life and symptoms in
patients with rituximab-refractory indolent non-Hodgkin lympho-
ma treated in the phase III GADOLIN study with obinutuzumab
plus bendamustine versus bendamustine alone. Ann Hematol
96(2):253–259. https://doi.org/10.1007/s00277-016-2878-5
13. Webster K, Cashy J, Cella D (2005) Measuring quality of life
(QOL) in patients with non-Hodgkin's lymphoma (NHL): the
Functional Assessment of Cancer Therapy-LYmphoma (FACT-
LYM). Qual Life Res 14(9):Abstract 650
14. McGlothlin AE, Lewis RJ (2014) Minimal clinically important dif-
ference: defining what really matters to patients. JAMA 312(13):
1342–1343. https://doi.org/10.1001/jama.2014.13128
15. Harrison CN, Mesa RA, Kiladjian JJ, Al-Ali HK, Gisslinger H,
Knoops L, Squier M, Sirulnik A, Mendelson E, Zhou X, Copley-
Merriman C, Hunter DS, Levy RS, Cervantes F, Passamonti F,
Barbui T, Barosi G, Vannucchi AM (2013) Health-related quality
of life and symptoms in patients with myelofibrosis treated with
ruxolitinib versus best available therapy. Br J Haematol 162(2):
229–239. https://doi.org/10.1111/bjh.12375
16. Carter GB, Liepa AM, Zimmermann AH, Morschhauser F (2008)
Validation of the functional assessment of cancer therapy–
lymphoma (FACT-LYM) in patients with relapsed/refractory man-
tle cell lymphoma. Blood 112:2376
17. Webster K, Cella D, Yost K (2003) The Functional Assessment of
Chronic Illness Therapy (FACIT) measurement system: properties,
applications, and interpretation. Health Qual Life Outcomes 1:79.
https://doi.org/10.1186/1477-7525-1-79
18. Townsend W, Buske C, Cartron G, Cunningham D, Dyer M,
Gribben JG, Hess G, Ishikawa T, Keller U, Kneba M, Malladi R,
Neidhart JD, Rusconi C, Zhu J, Catalani O, Knapp A, Zeuner H,
Herold M, Hiddemann W, Marcus R (2018) Obinutuzumab-based
immunochemotherapy prolongs progression-free survival and time
to next anti-lymphoma treatment in patients with previously un-
treated follicular lymphoma: four-year results from the phase III
GALLIUM study. ASH Annual Meeting: Abstract 1597
19. KangD, Cho J, Kim IR, KimMK,KimWS, Kim SJ (2018) Health-
related quality of life in non-Hodgkin lymphoma survivors: a pro-
spective cohort study. Cancer Res Treat : 50(4):1051–1063. https://
doi.org/10.4143/crt.2017.207
20. Arden-Close E, Pacey A, Eiser C (2010) Health-related quality of
life in survivors of lymphoma: a systematic review and methodo-
logical critique. Leuk Lymphoma 51(4):628–640. https://doi.org/
10.3109/10428191003587263
21. Kristensen A, Solheim TS, Amundsen T, Hjelde HH, Kaasa S,
Sorhaug S, Gronberg BH (2017) Measurement of health-related
quality of life during chemotherapy - the importance of timing.
Acta Oncol 56(5):737–745. https://doi.org/10.1080/0284186X.
2017.1279748
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Ann Hematol
Affiliations
Andrew Davies1 & Peter Trask2 & Judit Demeter3 & Axel Florschütz4 &Mathias Hänel5 & Tomohiro Kinoshita6 &
Ruth Pettengell7 &Hang Quach8 & Stephen Robinson9 & Shalal Sadullah10 & Juan-Manuel Sancho11 &Miklos Udvardy12 &
Mathias Witzens-Harig13 & Andrea Knapp14 &Wenxin Liu14
1 Cancer Research UK Centre, Centre for Cancer Immunology,
Faculty of Medicine, University of Southampton, Southampton
General Hospital, Southampton SO16 6YD, UK
2 Genentech Inc., South San Francisco, CA, USA
3 Semmelweis University, Budapest, Hungary
4 Städtisches Klinikum Dessau, Dessau-Roßlau, Germany
5 Klinikum Chemnitz gGmbH, Chemnitz, Germany
6 Aichi Cancer Center Hospital, Aichi, Japan
7 St George’s University, London, UK
8 University of Melbourne and St. Vincent’s Hospital,
Melbourne, Australia
9 Bristol Haematology and Oncology Centre, Bristol, UK
10 James Paget Hospital, Great Yarmouth, UK
11 ICO-IJC-Hospital Germans Trias i Pujol, Barcelona, Spain
12 Medical and Health Science Centre, University of Debrecen,
Debrecen, Hungary
13 Uniklinik Heidelberg, Heidelberg, Germany
14 F. Hoffmann-La Roche Ltd, Basel, Switzerland
Ann Hematol
